Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue and operating profit increased due to factors affecting each segment. Ordinary profit increased due to higher operating profit and an increase in foreign exchange gains. Net income attributable to owners of the parent increased due to higher ordinary profit and the recognition of a gain on sale of investment securities. The Life Sciences business saw lower revenue and higher profit, while the Electronic Materials business saw higher revenue and profit.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥76,926 million (YoY +10.7%) |
| Operating profit | ¥18,850 million (YoY +16.1%) |
| Ordinary income | ¥19,573 million (YoY +18.2%) |
| Profit attributable to owners of the parent | ¥14,311 million (YoY +23.1%) |
| Net income per share | ¥135.28 |
| Operating Margin | 24.5% |
| Equity ratio | End of the current fiscal period 77.0% / End of previous period 73.5% |
| Total assets | ¥152,256 million |
| Net assets | ¥117,216 million |
| Cash flows from operating activities | ¥24,793 million |
| Cash flows from investing activities | ¥-11,069 million |
| Cash flows from financing activities | ¥-5,905 million |
| Cash and cash equivalents at end of period | ¥37,896 million |
| Full-year earnings forecast | Net Sales ¥85,800 million (YoY +11.5%) / Operating profit ¥24,300 million (YoY +28.9%) / Ordinary income ¥24,500 million (YoY +25.2%) / Profit attributable to owners of the parent ¥16,600 million (YoY +16.0%) |
| Annual Dividend Forecast | ¥82.00 (actual for the fiscal year ending March 2026, before the stock split) → ¥28.00 (forecast for the fiscal year ending March 2027, after the stock split)（Not directly comparable） |
| Payout ratio | 20.2% |
| Segment revenue | Life Sciences Business ¥35,411,140 thousand (YoY -2.4%), Electronic Materials Business ¥41,514,883 thousand (YoY +25.0%) |
| Segment profit | Life Sciences Business ¥5,308,248 thousand (YoY +0.4%), Electronic Materials Business ¥15,926,679 thousand (YoY +20.9%) |
| Regional sales | ¥34,530,791 thousand, ¥674,708 thousand, ¥12,126,603 thousand, ¥29,500,297 thousand, ¥93,622 thousand, ¥76,926,023 thousand |
| Depreciation and amortization | ¥10,936,736 thousand |
| Impairment loss | ¥1,903 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2,838 thousand, Gain on sale of investment securities ¥184,916 thousand, Subsidy Income ¥5,588 thousand / Extraordinary loss Loss on sale of fixed assets ¥207 thousand, Loss on Disposal of Fixed Assets ¥217,725 thousand, Impairment Losses ¥1,903 thousand, Loss on valuation of investments ¥18,869 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions, 0 exclusions (no material changes) |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 106,533,000 |
| Treasury Shares at Period-End | 736,626 |
| Factors Behind Changes in Business Performance | Revenue and operating profit increased due to factors affecting each segment. Ordinary profit increased due to higher operating profit and an increase in foreign exchange gains. Net income attributable to owners of the parent increased due to higher ordinary profit and the recognition of a gain on sale of investment securities. The Life Sciences business saw lower revenue and higher profit, while the Electronic Materials business saw higher revenue and profit. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and operating profit increased due to factors affecting each segment. In the Electronic Materials business, growth in semiconductor market demand, particularly for AI applications, increased sales volumes to Asia and the effects of expanded production contributed to results. In the Life Sciences business, profit was lifted by the elimination of cost increases caused by the extended scheduled maintenance shutdown at the Kashima site in the previous fiscal year, lower raw material prices and contributions from overseas subsidiaries.